CStone Pharmaceuticals Unveils Groundbreaking Updates on CS2009 at ASCO 2026 Conference

CStone Pharmaceuticals Unveils Groundbreaking Updates on CS2009 at ASCO 2026

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, CStone Pharmaceuticals presented new clinical data that sheds light on its innovative trispecific antibody, CS2009, which targets PD-1, VEGF, and CTLA-4. This groundbreaking agent demonstrates significant potential to transform the landscape of cancer immunotherapy, particularly in treating both non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

CS2009 in First-line NSCLC Treatment

A standout finding from CStone’s study was the remarkable effectiveness of CS2009 in first-line NSCLC patients expressing high PD-L1 levels (TPS ≥50%). In this cohort, CS2009 as a monotherapy achieved an objective response rate (ORR) of 81.3% and a stunning disease control rate (DCR) of 100%. These effects were consistent across both squamous (ORR 87.5%) and non-squamous (ORR 75%) histologies. Adding to the excitement was the performance of CS2009 in PD-L1-negative/low patients, where a combination of CS2009 with chemotherapy yielded an ORR of 75% and a DCR of 100%, featuring a 100% ORR among the sub-group of patients with a TPS <1%.

Overcoming Treatment Resistance in Later-line NSCLC

In patients with heavily pretreated later-line NSCLC, CS2009 showcased promising antitumor activity, with most participants experiencing tumor shrinkage. Notably, across all dose levels, the six-month duration of response rate reached an impressive 85.7%. In a combination cohort involving second- and third-line treatment, CS2009 boasted an ORR of 66.7% and a DCR of 100%. Furthermore, CS2009 monotherapy in those whose disease progressed after prior immunotherapy achieved an ORR of 30.8%, highlighting its potential as a remedy for treatment-resistant cases.